最新业绩显示，金达威境外销售占比虽超境内，但境内营收增长率远超境外。具体来看，2025年上半 年，境外销售为13.02亿元，占营收比重75.32%，同比增长5.89%；境内销售为4.27亿元，占营收比重 24.68%，同比增长45.14%。 金达威在互动平台向投资者表示，将持续加强doctor's best在国内的销售力度，着重开发新媒体渠道的多 方面价值，通过产品品质和渠道建设共同推进品牌影响力。目前doctor's best除部分NMN（β-烟酰胺单 核苷酸）、麦角硫因来自于香港，其余成品全部在美国本土生产。 此外，《财经新康养》注意到，2025年上半年，金达威营收净利润双增背后，不同系列产品的营收占比 和销售趋势各不相同。例如，金达威营养保健食品营收占比最高但处于同比下滑趋势，维生素A系列营 收占比最小，但同比增长213.06%。 据悉，维生素A是饲料喂养过程中的元素，是一种饲料添加剂，由于合成工艺复杂，技术壁垒高，中小 企业难以进入，市场格局较为稳定。金达威指出，维生素A系列产品2024年同期受安全事故影响曾阶段 性停产，导致可比基数较低；2025年工厂已恢复正常运行，产、销量相应回升，其中2025年 ...

Group 1: Company Operations and Market Position - The company is the largest producer of Coenzyme Q10 globally, recognized for its quality and production capacity, which is at the industry's leading level [2][3] - The company has undergone capacity expansion and transformation, significantly reducing production costs and increasing market share, thereby reinforcing its dominant market position [3] - Coenzyme Q10 is widely used in cardiovascular health and anti-aging sectors, with market demand expected to continue growing due to global aging and rising health awareness [3] Group 2: Product Development and Market Strategy - The company plans to closely monitor developments in the health and biosynthesis sectors, aligning R&D projects with market prospects and enhancing its synthetic biology research platform [2] - The company aims to strengthen its raw material supply chain and accelerate the industrialization of new products, focusing on biosynthesis research and global brand strategy [3] - The company is committed to building a strong brand presence in the health supplement market through a "big product + product matrix" strategy, leveraging both raw material and brand advantages [3] Group 3: Competitive Landscape - The U.S. dietary supplement market is highly fragmented, with the company focusing on maintaining its operational philosophy and differentiation to enhance market share for its star products [3] - The Doctor's Best brand emphasizes the use of high-quality raw materials and targets consumers interested in scientifically formulated nutrition, maintaining a leading position in the market [3]

Group 1: Overall Business Performance - In the first half of 2025, the company's total revenue reached 17.28 billion yuan, a 13.46% increase compared to the same period last year [2] - The net profit attributable to shareholders was 90.12 million yuan, reflecting a 2.47% growth year-on-year [2] Group 2: Nutritional Raw Materials Business - The company specializes in the large-scale production of products such as Coenzyme Q10, DHA, ARA, NMN, and Vitamin K2, among others [3] - Coenzyme Q10 holds the largest global market share, with a significant increase in gross margin due to production scale effects and technological improvements [3] - The company is investing in new product development using synthetic biology and microbial fermentation technologies [3] Group 3: Coenzyme Q10 Business - Coenzyme Q10 is increasingly recognized for its health benefits, leading to a growing market demand, particularly in China due to aging population and upgraded health awareness [3] - The company is the largest global producer of Coenzyme Q10, exporting to numerous countries and regions [3] - Expansion plans are in place to meet the rising market demand and strengthen the company's leading position in the industry [3] Group 4: Nutritional Supplements Business - The company owns several brands, including Doctor's Best and Zipfizz, with production services provided by its U.S. subsidiary, VitaBest [4] - Sales of Doctor's Best and Zipfizz experienced a decline in the first half of 2025 due to inventory control and purchasing adjustments by downstream customers [5] - The company is focusing on brand building and enhancing marketing efforts to improve sales channels and brand influence [5] Group 5: Domestic Nutritional Supplements Business - The domestic market for nutritional supplements is primarily served through online channels like Tmall and JD.com, with growth driven by the increasing demand for cross-border e-commerce [5] - The company aims to enhance operational efficiency and expand its market share in domestic self-owned brands [5]